ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies
SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]
ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible
Shares of ADMA Biologics [NASDAQ:ADMA] fell more than 45% on [...]
ADMA Biologics Receives a Split FDA Decision on BIVIGAM
ADMA Biologics (NASDAQ:ADMA), a company specializing in the manufacturing and development [...]
ADMA Biologics (NASDAQ:ADMA) December Catalyst: PDUFA for BIVIGAM
SanaCurrents assigns a pivotal sentiment the FDA will approve the [...]